Phase I trial with carboplatin and RAD001 in metastatic breast cancer

被引：0
|
作者：
Eucker, J.
Schwarzlose-Schwarck, S.
Martus, P.
Regierer, A. C.
Schulz, C. O.
Liu, H.
Scholz, C. W.
Schefe, J. H.
Possinger, K.
机构：
[1] Charite, Dept Hematol & Oncol, Berlin, Germany
[2] Charite, Inst Biostat & Clin Epidemiol, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11554
引用
收藏
页数：2
相关论文
共 50 条
  • [31] RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumah in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial
    O'Regan, R.
    Andre, F.
    Campone, M.
    Naughton, M.
    Manlius, C.
    Pylvaenaeinen, I
    Sahmoud, T.
    Hurvitz, S.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 237S - 237S
  • [32] The mTOR Inhibitor Everolimus in Combination with Carboplatin in Metastatic Breast Cancer - a Phase I Trial
    Schwarzlose-Schwarck, Sandra
    Scholz, Christian W.
    Regierer, Anne C.
    Martus, Peter
    Neumann, Christian
    Habbel, Piet
    Liu, Hongyu
    Zang, Chuanbing
    Schefe, Jan-Hendrik
    Schulz, Carsten-Oliver
    Possinger, Kurt
    Eucker, Jan
    [J]. ANTICANCER RESEARCH, 2012, 32 (08) : 3435 - 3441
  • [33] Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
    Su Jin Lee
    Jongtae Lee
    Jeeyun Lee
    Se Hoon Park
    Joon Oh Park
    Young Suk Park
    Ho Yeong Lim
    Kyoung-Mee Kim
    In-Gu Do
    Sin-Ho Jung
    Dong-Seok Yim
    Won Ki Kang
    [J]. Investigational New Drugs, 2013, 31 : 1580 - 1586
  • [34] Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients
    Lee, Su Jin
    Lee, Jongtae
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kim, Kyoung-Mee
    Do, In-Gu
    Jung, Sin-Ho
    Yim, Dong-Seok
    Kang, Won Ki
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (06) : 1580 - 1586
  • [35] Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer (MBC)
    Mayer, I. A.
    Means-Powell, J.
    Abramson, V. G.
    Shyr, Y.
    Balko, J. M.
    Kuba, M. G.
    Gharavii, H. M.
    Schlabach, L.
    Arteaga, C. L.
    Pietenpol, J. A.
    [J]. CANCER RESEARCH, 2011, 71
  • [36] A Phase II Trial of Fulvestrant and RAD001 (Everolimus) in Patients with Metastatic Estrogen Receptor Positive Breast Cancer after Aromatase Inhibitor Failure; a Study in Progress
    Badin, F.
    Romond, E.
    Chambers, M.
    Shelton, B.
    Birk, S.
    Kadamyan, V.
    Weiss, H.
    Massarweh, S.
    [J]. CANCER RESEARCH, 2010, 70
  • [37] Effects of the combination of RAD001 and docetaxel on breast cancer stem cells
    Zhang, Xiaobei
    Zhang, Sheng
    Liu, Yan
    Liu, Jingjing
    Ma, Yi
    Zhu, Yuanxi
    Zhang, Jin
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (10) : 1581 - 1592
  • [38] Preclinical studies of the combination of RAD001 with tamoxifen or letrozole in breast cancer
    不详
    [J]. EJC SUPPLEMENTS, 2006, 4 (02): : 142 - 142
  • [39] Combination of carboplatin and the mTor inhibitor RAD001 is a new therapeutic approach for p53-mutated breast cancer
    Lin, H.
    Possinger, K.
    Eucker, J.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 93S - 93S
  • [40] Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab
    Fasolo, A.
    Gianni, L.
    Rorive, A.
    Bergh, J.
    Dieras, V
    Cardoso, F.
    Vittori, L.
    Pylvaenaeinen, I
    Sahmoud, T.
    Jerusalem, G.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 93S - 93S
12345